Consolidated profit and loss accounts: from operating profit to net profit excluding non-recurring items:
| € millions | 2020 | 2021 | 2022 | Evolution |
|---|---|---|---|---|
| Operating profit | Operating profit20205,209.0 | Operating profit20216,160.3 | Operating profit20227,456.9 | +21% |
| Financial revenues and expenses excluding Sanofi dividends | Financial revenues and expenses excluding Sanofi dividends 2020-95.9 |
Financial revenues and expenses excluding Sanofi dividends 2021-59.6 |
Financial revenues and expenses excluding Sanofi dividends 2022-73.0 |
Financial revenues and expenses excluding Sanofi dividends Evolution
|
| Sanofi dividends | Sanofi dividends 2020372.4 |
Sanofi dividends 2021378.3 |
Sanofi dividends 2022468.2 |
Sanofi dividends Evolution
|
| Profit before tax excluding non-recurring items | Profit before tax excluding non-recurring items20205,485.5 | Profit before tax excluding non-recurring items20216,478.9 | Profit before tax excluding non-recurring items20227 852.1 | Profit before tax excluding non-recurring itemsEvolution+21.2% |
| Income tax excluding non-recurring items | Income tax excluding non-recurring items 2020-1,383.1 |
Income tax excluding non-recurring items 2021-1,535.6 |
Income tax excluding non-recurring items 2022-1,793.4 |
Income tax excluding non-recurring items Evolution
|
| Net profit excluding non-recurring items of equity consolidated companies | Net profit excluding non-recurring items of equity consolidated companies 2020+0.9 |
Net profit excluding non-recurring items of equity consolidated companies 2021+0.6 |
Net profit excluding non-recurring items of equity consolidated companies 2022+1.5 |
Net profit excluding non-recurring items of equity consolidated companies Evolution
|
| Non-controlling interests | Non-controlling interests 2020-4.2 |
Non-controlling interests 2021-5.5 |
Non-controlling interests 2022- 6.1 |
Non-controlling interests Evolution
|
| Net profit excluding non-recurring items after non-controlling interests | Net profit excluding non-recurring items after non-controlling interests20204,099.0 | Net profit excluding non-recurring items after non-controlling interests20214,938.5 | Net profit excluding non-recurring items after non-controlling interests20226,054.1 | Net profit excluding non-recurring items after non-controlling interestsEvolution+22.6% |
| EPS (1) (€) | EPS (1)(€) 20207.30 |
EPS (1)(€) 20218.82 |
EPS (1)(€) 202211.26 |
EPS (1)(€) Evolution+27.6% |
| NET PROFIT AFTER NON-CONTROLLING INTERESTS | NET PROFIT AFTER NON-CONTROLLING INTERESTS20203,563.4 | NET PROFIT AFTER NON-CONTROLLING INTERESTS20214,597.1 | NET PROFIT AFTER NON-CONTROLLING INTERESTS20225,706.6 | NET PROFIT AFTER NON-CONTROLLING INTERESTSEvolution+ 24.10% |
| Diluted EPS after non-controlling interests (€) | Diluted EPS after non-controlling interests (€) 20206.34 |
Diluted EPS after non-controlling interests (€) 20218.21 |
Diluted EPS after non-controlling interests (€) 202210.61 |
Diluted EPS after non-controlling interests (€) Evolution
|
| Diluted average number of shares | Diluted average number of shares 2020561,635,963 |
Diluted average number of shares 2021559,791,545 |
Diluted average number of shares 2022537,657,548 |
Diluted average number of shares Evolution
|
(1) Diluted earnings per share, based on net profit, excluding non-recurring items, after non-controlling interests.
Net finance costs amounted to 73 million euros.
Sanofi dividends totalled 468.2 million euros. This year, in addition to the annual dividend of 393.7 million euros, Sanofi paid an additional dividend-in-kind in the form of newly listed Euroapi shares for an amount of 74.5 million euros.
Income tax excluding non-recurrent items amounted to1,793 million euros, representing a tax rate of 22.8%.
Net profit excluding non-recurring items after non-controlling interests stood at 6,054 million euros.
Earnings per share(1), at 11.26 euros, increased by +27.6%.
Non-recurring items after non-controlling interests(2) amounted to 347 million euros net of tax.
Net profit after non-controlling interests came out at 5,706 million euros, increasing by +24.1%.
Gross cash flow amounted to 7,289 million euros, an increaseof +9.8%.
The working capital requirement increased by 1,010 million euros.
At 1,343.2 million euros, investments represented 3.5% of sales.
Net cash flow(3), at 4,935 million euros, decreased by 12.7%.
The balance sheet remains strong, with shareholders’ equity amounting to 27.2 billion euros.
The Board of Directors has decided to propose a dividend of6.00 euros per share at the shareholders’ Annual GeneralMeeting of 21 April 2023, an increase of +25% comparedwith the dividend paid in 2022. The dividend will be paid on28 April 2023 (ex-dividend date 26 April at 0:00am, Paris time).
At 31 December 2022, the capital of the company is formed by 535,186,562 shares.
(1) Diluted earnings per share, based on net profit, excluding non-recurring items, after non-controlling interests.
(2) Non-recurring items include impairment of assets, capital gains and losses on disposals of long-term assets, restructuring costs and tax effects of non-recurring items.
(3) Net cash flow = Gross cash flow + changes in working capital - capital expenditure.
